WEN-JEN HWU to Biomarkers, Tumor
This is a "connection" page, showing publications WEN-JEN HWU has written about Biomarkers, Tumor.
Connection Strength
0.547
-
Pathology-based Biomarkers Useful for Clinical Decisions in Melanoma. Arch Med Res. 2020 11; 51(8):827-838.
Score: 0.199
-
Telomerase Reverse Transcriptase Protein Expression Is More Frequent in Acral Lentiginous Melanoma Than in Other Types of Cutaneous Melanoma. Arch Pathol Lab Med. 2021 07 01; 145(7):842-850.
Score: 0.052
-
TERT amplification but not activation of canonical Wnt/?-catenin pathway is involved in acral lentiginous melanoma progression to metastasis. Mod Pathol. 2020 10; 33(10):2067-2074.
Score: 0.048
-
Aberrant expression of FLI-1 in melanoma. J Cutan Pathol. 2017 Sep; 44(9):790-793.
Score: 0.040
-
High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients. Melanoma Res. 2017 02; 27(1):24-31.
Score: 0.039
-
Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol. 2015 Aug; 46(8):1101-10.
Score: 0.034
-
Correlation between lipid-associated sialic acid and tumor burden in melanoma. Int J Biol Markers. 1994 Oct-Dec; 9(4):247-50.
Score: 0.033
-
Neuron-specific enolase as a tumor marker in metastatic melanoma. Am J Clin Oncol. 1994 Oct; 17(5):430-1.
Score: 0.033
-
Eruptive melanotic macules and papules associated with adenocarcinoma. J Cutan Pathol. 2003 Aug; 30(7):463-9.
Score: 0.015
-
BAP-1 Expression Status by Immunohistochemistry in Cellular Blue Nevus and Blue Nevus-like Melanoma. Am J Dermatopathol. 2020 May; 42(5):313-321.
Score: 0.012
-
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nat Commun. 2020 04 15; 11(1):1839.
Score: 0.012
-
Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. Clin Cancer Res. 2018 04 15; 24(8):1805-1815.
Score: 0.010
-
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379).
Score: 0.010
-
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol. 2016 12; 34(34):4102-4109.
Score: 0.009